The diagnostic value of circulating microRNAs for middle-aged (40–60-year-old) coronary artery disease patients

Clinics

Volumn 70, Issue 4, 2015, Pages 257-263

  Sayed, Ali Sheikh Md ^a   Xia, Ke ^a,b   Li, Fei ^a   Deng, Xu ^a   Salma, Umme ^c   Li, Tingbo ^c   Deng, Hai ^a   Yang, Dafeng ^a   Haoyang, Zhou ^a   Yang, TianLun ^a   Peng, Jun ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biomarkers; Circulating microRNAs; Coronary artery disease; Non coronary artery disease; Unstable angina

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MIRN149 MICRORNA, HUMAN; MIRN424 MICRORNA, HUMAN; MIRN765 MICRORNA, HUMAN;

AGE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MALE; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; BIOMARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84930246988     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2015(04)07     Document Type: Article

References (44)

1. Braza-Boils A, Mari-Alexandre J, Molina P, Domingo D, Abellan Y, Sancho J, et al. P62Role of microRNAs associated with non-alcoholic fatty liver disease in sudden cardiac death from coronary artery disease. Cardiovasc Res. 2014;103(Suppl 1):S10.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-292, http://dx. doi.org/10.1161/01.cir.0000441139.02102.80.
3. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010;3(5):484-8, http://dx.doi.org/10.1161/CIRCGENETICS.110.958363.
4. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93(4):633-44, http://dx.doi.org/10.1093/cvr/cvs007.
5. Peng Y, Song L, Zhao M, Harmelink C, Debenedittis P, Cui X, et al. Critical roles of miRNA-mediated regulation of TGFb signalling during mouse cardiogenesis. Cardiovasc Res. 2014;103(2):258-67, http://dx.doi.org/ 10.1093/cvr/cvu126.
6. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336-42, http://dx.doi.org/10.1038/nature09783.
7. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79(4):562-70, http:// dx.doi.org/10.1093/cvr/cvn137.
8. Dangwal S, Bang C, Thum T. Novel techniques and targets in cardiovascular microRNA research. Cardiovasc Res. 2012;93(4):545-54, http:// dx.doi.org/10.1093/cvr/cvr297.
9. Mar-Aguilar F, Rodríguez-Padilla C, Reséndez-Pérez D. Use of serumcirculating miRNA profiling for the identification of breast cancer biomarkers. Methods Mol Biol. 2014;1165:71-80, http://dx.doi.org/10.1007/ 978-1-4939-0856-1.
10. Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011;118(4):217-26, http://dx.doi.org/10.1159/000328869.
11. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003-8, http://dx.doi.org/10.1073/pnas.1019055108.
12. Sayed AS, Xia K, Salma U, Yang T, Peng J. Diagnosis, Prognosis and Therapeutic Role of Circulating miRNAs in Cardiovascular Diseases. Heart Lung Circ. 2014;23(6):503-10, http://dx.doi.org/10.1016/j.hlc.2014.01.001.
13. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation. 2010;121(8):1022-32, http://dx.doi. org/10.1161/CIRCULATIONAHA.109.889048.
14. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677-84, http://dx.doi.org/10.1161/CIRCRESAHA.109.215566.
15. Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, et al. Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J. 2014;35(31):2106-14, http://dx.doi.org/10.1093/eurheartj/ehu151.
16. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51(5):872-5, http://dx. doi.org/10.1016/j.yjmcc.2011.07.011.
17. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659-66, http://dx.doi.org/ 10.1093/eurheartj/ehq013.
18. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147-54, http://dx.doi.org/10.1093/eurjhf/hfr155.
19. McManus DD, Lin H, Tanriverdi K, Quercio M, Yin X, Larson MG, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm. 2014;11(4):663-9, http://dx.doi.org/10.1016/j.hrthm.2014.01.018.
20. Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT, Juo SH. Serum microRNA-21 and microRNA-221 as Potential Biomarkers for Cerebrovascular Disease J Vasc Res. 2013;50(4):346-54, http://dx.doi.org/10.1159/000351767.
21. Waters PS, Dwyer RM, Brougham C, Glynn CL, Wall D, Hyland P, et al. Impact of tumour epithelial subtype on circulating microRNAs in breast cancer patients. PLoS One. 2014;9(3):e90605, http://dx.doi.org/10.1371/ journal.pone.0090605.
22. CorstenMF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating microRNA-208b and microRNA-499 reflectmyocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3(6):499-506, http:// dx.doi.org/10.1161/CIRCGENETICS.110.957415.
23. Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci. 2012;8(6):811-8, http://dx.doi. org/10.7150/ijbs.4439.
24. Peng L, Chun-guang Q, Bei-fang L, Xue-zhi D, Zi-hao W, Yun-fu L, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol. 2014;1(9):89, http://dx.doi.org/10.1186/1746-1596-9-89.
25. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035-9, http://dx.doi.org/10.1161/CIRCRESAHA.110.218297.
26. Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 2013;15(10):1138-47, http://dx. doi.org/10.1093/eurjhf/hft078.
27. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60 (24):e44-e164, http://dx.doi.org/10.1016/j.jacc.2012.07.013.
28. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-- 2002: summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of PatientsWith Unstable Angina). Circulation. 2002;106 (14):1893-??1900, http://dx.doi.org/10.1161/01.CIR.0000037106.76139.53.
29. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004;148(1):7-15, http://dx.doi.org/ 10.1016/j.ahj.2003.11.027.
30. Kumar S, Kim CW, Simmons RD, Jo H. Role of Flow-Sensitive microRNAs in Endothelial Dysfunction and Atherosclerosis: Mechanosensitive Athero-miRs. Arterioscler Thromb Vasc Biol. 2014;34(10):2206-16, http:// dx.doi.org/10.1161/ATVBAHA.114.303425.
31. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4):368-76, http:// dx.doi.org/10.1038/nm.3487.
32. Chen WJ, Zhang M, Zhao GJ, Fu Y, Zhang DW, Zhu HB, et al. MicroRNA- 33 in atherosclerosis etiology and pathophysiology. Atherosclerosis. 2013;227(2):201-8, http://dx.doi.org/10.1016/j.atherosclerosis.2012.11.025.
33. Wang H, Zhu HQ, Wang F, Zhou Q, Gui SY, Wang Y. MicroRNA-1 prevents high-fat diet-induced endothelial permeability in apoE knock-out mice. Mol Cell Biochem. 2013;378(1-2):153-9.
34. Muñoz-Pacheco P, Ortega-Hernández A, Miana M, Cachofeiro V, Fernández-Cruz A, Gómez-Garre D. Ezetimibe inhibits PMAinduced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. Pharmacol Res. 2012;66(6):536-43.
35. Gao S, Wassler M, Zhang L, Li Y, Wang J, Zhang Y, et al. MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis. 2014;232(1):171-9, http://dx.doi.org/10.1016/j.atherosclerosis.2013.11.029.
36. Hsu A, Chen SJ, Chang YS, Chen HC, Chu PH. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed Res Int. 2014;418628.
37. D'Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B, Devanna P, et al. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS One. 2013;8(11):e80345, http://dx. doi.org/10.1371/journal.pone.0080345.
38. Wu C, Gong Y, Sun A, Zhang Y, Zhang C, Zhang W, et al. The human MTHFR rs4846049 polymorphism increases coronary heart disease risk through modifying miRNA binding. Nutr Metab Cardiovasc Dis. 2013; 23(7):693-8, http://dx.doi.org/10.1016/j.numecd.2012.02.009.
39. Jeon YJ, Kim OJ, Kim SY, Oh SH, Oh D, Kim OJ, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol. 2013;33(2):420-30, http://dx.doi.org/10.1161/ATVBAHA.112.300251.
40. Palmieri D, Capponi S, Geroldi A, Mura M, Mandich P, Palombo D. TNFa induces the expression of genes associated with endothelial dysfunction through p38MAPK-mediated down-regulation of miR-149. Biochem Biophys Res Commun. 2014;443(1):246-51, http://dx.doi.org/ 10.1016/j.bbrc.2013.11.092.
41. Van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13027-32, http://dx.doi.org/10.1073/pnas.0805038105.
42. Zhao H, Wang J, Gao L, Wang R, Liu X, Gao Z, et al. MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke. 2013;44(6):1706-13, http://dx.doi. org/10.1161/STROKEAHA.111.000504.
43. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19(1):74-82.
44. Redell JB, Moore AN,Ward NH 3rd, Hergenroeder GW, Dash PK. Human traumatic brain injury alters plasma microRNA levels. J Neurotrauma. 2010;27(12):2147-56, http://dx.doi.org/10.1089/neu.2010.1481.